Financial Performance - The company's total adjusted EBITDA for 3Q25 was $610.3 million[6], compared to $538.9 million in 3Q24[6] - For the nine months ended September 30, 2025, the adjusted net income attributable to Labcorp Holdings Inc was $1038.3 million, compared to $939.9 million for the same period in 2024[22] - The adjusted earnings per share for the three months ended September 30, 2025, was $4.18, compared to $3.50 for the same period in 2024[23] Revenue Analysis - Enterprise revenues, as reported, for 3Q25 were $3,564 million, an increase of 8.6% year-over-year[8] - Diagnostics Laboratories revenues, as reported, for 3Q25 were $2,770 million, an increase of 8.5% year-over-year[8] - Biopharma Laboratory Services revenues, as reported, for 3Q25 were $799 million, an increase of 8.3% year-over-year[8] - The company's revenue growth in Diagnostics Laboratories for 3Q25 was primarily driven by volume (4.7%) and price/mix (3.7%)[15] Outlook for 2025 - The company updated its 2025 revenue guidance for Labcorp Enterprise to a range of $13.97 billion to $14.05 billion, representing a growth of 7.4% to 8.0% versus 2024 results[18] - The company updated its 2025 adjusted EPS guidance to a range of $16.15 to $16.50, representing a growth of 10.8% to 13.2% versus 2024 results[18] Biopharma Laboratory Services - The trailing twelve-month net orders for Biopharma Laboratory Services ending September 30, 2025, were $3.34 billion, with a net book-to-bill ratio of 1.09x[17]

Core Insights - The U.S. market is experiencing significant turbulence due to renewed U.S.-China trade tensions, an ongoing government shutdown, and the start of the third-quarter earnings season [1][11] - Investors are closely monitoring key reports on inflation and jobs, as well as remarks from Fed Chair Powell that may influence rate expectations [2] - Amidst these uncertainties, value investing is gaining traction, focusing on fundamentally strong companies that are undervalued [2][11] Value Investing and Earnings Yield - Earnings yield is a crucial metric for identifying attractive value opportunities, calculated as annual earnings per share (EPS) divided by the market price [4] - Stocks with higher earnings yield are considered undervalued compared to those with lower earnings yield, which are seen as overpriced [5] - A stock's yield should be compared to the 10-year Treasury yield to assess its relative value; a higher yield indicates a potentially better investment for value investors [6] Screening Criteria for Stock Selection - The primary screening criterion is an earnings yield greater than 10%, supplemented by additional parameters such as estimated EPS growth and average daily trading volume [7][8] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform peers in various market conditions [9] Top Stock Picks - **Allied Gold Corporation (AAUC)**: Expected EPS growth of 907% and 193% for 2025 and 2026, respectively, with a Zacks Rank 1 [12] - **Micron Technology Inc. (MU)**: Anticipated EPS growth of 100% and 12% for fiscal 2026 and 2027, respectively, also holding a Zacks Rank 1 [13] - **Fortrea Holdings Inc. (FTRE)**: Projected EPS growth of 63.6% and 64.5% for 2025 and 2026, with a Zacks Rank 1 [14] - **StoneCo Ltd. (STNE)**: Expected EPS growth of 20% and 17% for 2025 and 2026, respectively, and a Zacks Rank 1 [15] - **HF Sinclair Corporation (DINO)**: Forecasted EPS growth of 257.4% and 26.4% for 2025 and 2026, with a Zacks Rank 1 [16]

Core Insights - Fortrea Holdings Inc. is identified as a cheap stock with potential for growth over the next five years, with Barclays raising its price target to $8 from $6 while maintaining an Underweight rating [1][3] Financial Performance - In Q2, Fortrea reported quarterly revenue of $710.3 million, reflecting a year-over-year increase of 7.23% [1][2] - The company achieved an Adjusted EBITDA of $54.9 million and an adjusted net income per diluted share of $0.19, prompting management to raise its full-year 2025 revenue guidance to a range of $2.6 to $2.7 billion [2] - Despite revenue growth, Fortrea recorded a GAAP net loss of $374.9 million, or $4.14 per diluted share, primarily due to a non-cash goodwill impairment charge of $309.1 million [3] Business Overview - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers [4] - The company's backlog stood at $7.547 billion, indicating a strong pipeline of future business [3] - Fortrea affirmed that its cost-saving initiatives are on track, which may enhance future profitability [3]

Company Overview - Amarin (AMRN) shares increased by 12.5% to close at $18.84, supported by high trading volume, compared to an 11.4% gain over the past four weeks [1] - The price surge is linked to rising investor confidence in Vascepa, Amarin's sole marketed drug, which treats severe hypertriglyceridemia [1] Earnings Expectations - Amarin is projected to report quarterly earnings of $0.31 per share, reflecting a year-over-year increase of 131% [2] - Expected revenues are $42.36 million, showing a slight increase of 0.2% from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Amarin has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [4] Industry Comparison - Amarin operates within the Zacks Medical - Biomedical and Genetics industry, where Fortrea Holdings Inc. (FTRE) has seen a decline of 1.6% to $9.45, with a monthly return of -8.7% [4] - Fortrea's consensus EPS estimate has decreased by 13.3% over the past month to $0.15, representing a 34.8% decline from the previous year [5]

Core Viewpoint - A lawsuit is pending against Semtech Corporation (NASDAQ: SMTC) for alleged violations of securities laws, primarily related to the company's CopperEdge products not meeting customer needs, which could impact sales forecasts for fiscal 2026 [2][3]. Group 1: Lawsuit Details - The lawsuit was initiated by an investor on February 20, 2025, claiming that Semtech Corporation failed to disclose critical information regarding its CopperEdge products [2]. - Allegations include that the CopperEdge products required specific rack architecture changes and would not achieve expected sales growth during fiscal 2026, leading to misleading positive statements from the company [2]. - A consolidated complaint was filed on July 14, 2025, and the defendants submitted a motion to dismiss the case on August 11, 2025 [3]. Group 2: Investor Information - Investors who purchased shares of Semtech Corporation prior to August 2024 and continue to hold them are encouraged to contact the Shareholders Foundation for options regarding the lawsuit [1][3].

Company Overview - Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide [4] Financial Performance - For Q2 2025, Fortrea reported revenue of $710.3 million, an increase from $662.4 million in Q2 2024 [2] - The company experienced a GAAP net loss of $374.9 million, which included a non-cash goodwill impairment charge of $309.1 million, resulting in a GAAP loss of $4.14 per diluted share [2] - Despite the loss, Fortrea achieved a positive adjusted net income of $17.6 million, or $0.19 per diluted share, a turnaround from an adjusted net loss of $2.3 million in Q2 2024 [3] - Fortrea is increasing its 2025 revenue guidance to a range of $2,600 to $2,700 million and affirming its adjusted EBITDA guidance for the full year in the range of $170 million to $200 million [3] Market Sentiment - Jefferies raised the price target on Fortrea to $9.50 from $7 while maintaining a Hold rating, driven by stronger biotech funding in the last three months and improved bookings across the contract research organization industry [1][3]

Company Performance - AC Immune reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, marking an earnings surprise of -25.00% [1] - The company posted revenues of $1.58 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 57.3%, compared to revenues of $0.76 million a year ago [2] - Over the last four quarters, AC Immune has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [2] Stock Outlook - AC Immune shares have declined approximately 18.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.24 on revenues of $1.14 million, and for the current fiscal year, it is -$0.93 on revenues of $6.04 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AC Immune's stock performance [5][6]

Financial Performance - Q2 2025 - Total Adjusted EBITDA for Q2 2025 was $627.8 million[6], compared to $574.6 million in Q2 2024[6], an increase - The company's Q2 2025 revenue, as reported, reached $3.5273 billion[21], a 9.5% increase year-over-year from $3.2209 billion in Q2 2024[21] - Adjusted earnings per share for Q2 2025 was $4.35[23], compared to $3.94 in Q2 2024[23] Revenue Breakdown and Growth - Enterprise revenue, as reported, for Q2 2025 was $3.527 billion[8], reflecting a 9.5% year-over-year growth[8] - Diagnostics Laboratories revenue, as reported, for Q2 2025 was $2.749 billion[8], showing an 8.9% year-over-year growth[8] - Biopharma Laboratory Services revenue, as reported, for Q2 2025 was $785 million[8], a significant 11% increase year-over-year[8] Outlook for 2025 - The company projects full-year 2025 revenue for Labcorp Enterprise to be between $13.98 billion and $14.13 billion[18], representing a 7.5% to 8.6% increase versus 2024 results[18] - The company anticipates adjusted EPS for 2025 to be in the range of $16.05 to $16.50[18], a 10.1% to 13.2% increase compared to 2024[18] Biopharma Laboratory Services Metrics - The Trailing Twelve Month (TTM) Net Orders ending June 30, 2025, for Biopharma Laboratory Services reached $3.34 billion[17], with a Net Book-to-Bill ratio of 1.11x[17] - As of June 30, 2025, the backlog for Biopharma Laboratory Services was $8.71 billion[17], with an estimated $2.71 billion expected to convert to revenue in the next twelve months[17]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit without upfront costs [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].